Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Walker

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
British Journal of Haematology|July 10, 2021
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapseEileen M Boyle, Adam Rosenthal, Yan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPaola E Leone, Brian A Walker, Matthew W Jenner, et al.
Leukemia|July 3, 2013
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptomsBrian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Blood|August 23, 2017
Neutral tumor evolution in myeloma is associated with poor prognosisDavid C Johnson, Oleg Lenive, Jonathan Mitchell, et al.
British Journal of Haematology|July 10, 2021
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapseEileen M Boyle, Adam Rosenthal, Yan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Deletions of CDKN2C in multiple myeloma: biological and clinical implicationsPaola E Leone, Brian A Walker, Matthew W Jenner, et al.
Leukemia|July 3, 2013
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptomsBrian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
Blood|November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCharlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Blood|July 10, 2010
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic valueBrian A Walker, Paola E Leone, Laura Chiecchio, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Pageof 14